167.10
+6.68%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dishman Carbogen Amcis
Its shares trade on NSE under the ticker DCAL.NS. It has been listed since 21 September 2017. In the fiscal year to 31 March 2026, it reported revenue of ₹29.32bn and net income of ₹974.5m. At that date it held total assets of ₹119.23bn and shareholders' equity of ₹66.77bn.
Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 21 Sept 2017
- Employees
- 1,295
- Website
- carbogen-amcis.com ↗
Leadership
Pay as last reported
- Mr. Harshil DalalGlobal Chief Financial Officer
- Ms. Shrima DaveCompliance Officer, Company Secretary₹611,000
- Mr. Arpit VyasGlobal Managing Director, Executive Director, since 2009₹18.0m
- Mrs. Deohooti VyasWhole-Time Director₹12.0m
- Mr. Dhaval ShahNon-Executive Non-Independent Director
- Mr. Kulin ShahIndependent Director
- Mr. Hemantkumar Jayantiprasad BhattNon-Executive Independent Director
- Ms. Margie ParikhNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates manufacturing facilities in multiple countries including India and Switzerland.
- It provides comprehensive outsourcing services for the pharmaceutical industry.
- The firm has a global presence with subsidiaries in China and Singapore.
Weaknesses
- The employee base consists of only 1,295 full-time staff members.
- The company relies on specific segments like CRAMS and Vitamin D.
- It is a relatively young public company having listed in 2017.
Opportunities
- The firm can expand its drug development assistance to more pharma companies.
- New subsidiaries could facilitate growth in international markets.
- Supplying active pharmaceutical ingredients offers steady revenue streams.
Threats
- Regulatory changes in countries like France and the UK may impact operations.
- Competition in the life sciences tools and services sector is intense.
- Reliance on outsourcing services makes the business vulnerable to client shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.